|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 112.62 USD | -3.83% |
|
-6.13% | +6.98% |
| 02:45pm | Merck's Idvynso to Treat HIV-1 Infection Receives FDA Approval | MT |
| 02:13pm | Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says | MT |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 28.16x | 5.14x | -0.66x | 4.83x | 15x | 17.82x | 2.88% | 289B | ||
| 27.06x | 16.88x | 0.56x | 10.25x | 20.54x | 22.37x | 0.73% | 823B | ||
| 24.65x | 6.21x | -1.63x | 5.69x | 15.4x | 17.09x | 2.31% | 556B | ||
| 22.92x | 136.46x | 0.08x | 6.15x | 12.48x | 12.89x | 3.38% | 360B | ||
| 17.23x | 6.03x | 1.07x | 4.24x | 10.43x | 11.77x | 3.12% | 330B | ||
| 25.53x | 5.63x | 1.2x | 5.27x | 14.89x | 15.73x | 1.64% | 314B | ||
| 21.08x | 6.36x | 1101.19x | 5.65x | 13.68x | 14.96x | 2.9% | 290B | ||
| 23.01x | 16.74x | 3.31x | 6.08x | 10.7x | 13.81x | 2.88% | 189B | ||
| 12.22x | 5.17x | -1.46x | 4.39x | 9.18x | 10.8x | 4.23% | 180B | ||
| 18.45x | 6.1x | 2.14x | 5.77x | 10.62x | 12.49x | 2.42% | 169B | ||
| 12.5x | 1.77x | 0.2x | 3.3x | 7.95x | 9.29x | 6.37% | 157B | ||
| 12.06x | 5.13x | 0.29x | 3.16x | 8.32x | 9.12x | 4.27% | 121B | ||
| 12.09x | 1.29x | 2.01x | 2.37x | 7.62x | 8.53x | 5.19% | 117B | ||
| 13.56x | 4.44x | 1.13x | 2.88x | 8.46x | 9.53x | 3.26% | 116B | ||
| 25.22x | 4.96x | 1.85x | 7.58x | 17.08x | 17.73x | -.--% | 112B | ||
| 28.74x | 6.41x | 1.72x | 9.85x | 18.52x | 19.37x | 1.55% | 91.79B | ||
| 49.61x | 1.24x | 0.77x | 2.81x | 10.38x | 29.44x | 3.59% | 55.54B | ||
| 40.1x | 5.39x | 2.1x | 9.09x | 30.31x | 31.7x | 0.48% | 54.82B | ||
| 20.66x | 1.45x | -0.13x | 1.61x | 7.72x | 13.26x | 0.52% | 47.88B | ||
| 18.45x | 1.85x | 4.27x | 3.38x | 12.75x | 14.31x | 2.22% | 42.93B | ||
| Average | 22.67x | 12.23x | 56.00x | 5.22x | 13.10x | 15.60x | 2.7% | 220.74B | |
| Weighted average by Cap. | 22.75x | 18.56x | 72.79x | 6.10x | 14.21x | 15.98x | 2.5% |
- Stock Market
- Equities
- MRK Stock
- Sector Merck & Co., Inc.
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















